Fulcrum Therapeutics
FULC
130 hedge funds and large institutions have $196M invested in Fulcrum Therapeutics in 2024 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 32 increasing their positions, 35 reducing their positions, and 34 closing their positions.
254% more call options, than puts
Call options by funds: $25.5M | Put options by funds: $7.19M
26% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 34
7% more funds holding
Funds holding: 121 → 130 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 35
16.27% less ownership
Funds ownership: 104.28% → 88.01% (-16%)
51% less capital invested
Capital invested by funds: $402M → $196M (-$206M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$38.9M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$35.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.6M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$7.93M |
| 5 |
BlackRock
New York
|
+$6.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$36.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
| 3 |
CAC
Cowen and Company
New York
|
-$18.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$10.2M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$10.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
151
Semanteon Capital Management
Newton,
Massachusetts
| – | -$165K | -26,658 | Closed |
|
|
BM
152
Brandywine Managers
Hockessin,
Delaware
| – | -$162K | -26,127 | Closed |
|
153
Los Angeles Capital Management
Los Angeles,
California
| – | -$130K | -21,038 | Closed |
|
|
AIM
154
Aigen Investment Management
New York
| – | -$120K | -19,311 | Closed |
|
|
CANY
155
Caxton Associates (New York)
New York
| – | -$117K | -18,875 | Closed |
|
|
ACM
156
Aquatic Capital Management
Chicago,
Illinois
| – | -$107K | -17,300 | Closed |
|
|
QT
157
Quantbot Technologies
New York
| – | -$87K | -14,029 | Closed |
|
158
Renaissance Technologies
New York
| – | -$82.2K | -13,257 | Closed |
|
|
MTIM
159
Marathon Trading Investment Management
Radnor,
Pennsylvania
| – | -$67K | -10,800 | Closed |
|
|
LCM
160
Landscape Capital Management
Englewood,
New Jersey
| – | -$65K | -10,489 | Closed |
|
161
Belvedere Trading
Chicago,
Illinois
| – | -$29.6K | -3,988 | Closed |
|
|
BL
162
BFSG LLC
Irvine,
California
| – | -$15.6K | -2,510 | Closed |
|
163
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$37 | +5 | New |
|
FULC Hedge Fund Activity: Q3 2024 in Review
130 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2024, worth a combined $196M — down 51% from $402M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new FULC positions and 34 closed out — a net gain of 9 holders — while 32 added to existing stakes and 35 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $38.9M. The largest seller was RTW Investments, exiting entirely with an estimated $36.2M sold.
- 130 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2024, up from 121 in Q2 2024.
- Funds reported $196M of Fulcrum Therapeutics stock for Q3 2024, down 51% quarter-over-quarter.
- 43 funds opened new Fulcrum Therapeutics positions in Q3 2024 and 34 closed out, a net change of +9 holders.
- The largest Fulcrum Therapeutics buyer in Q3 2024 was TCG Crossover Management, an estimated $38.9M added.
- The largest Fulcrum Therapeutics seller in Q3 2024 was RTW Investments, an estimated $36.2M sold.
Based on aggregated 13F filings for Q3 2024.